• Careers
  • Contact
Intensity Therapeutics
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • Follow-on Programs
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • Follow-on Programs
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financials
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Events & Presentations
  • Email Alerts
Nov 13, 2023 8:01am EST

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Nov 02, 2023 7:01am EDT

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Sep 07, 2023 8:01am EDT

Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma

Sep 05, 2023 8:01am EDT

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023 7:01am EDT

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Aug 07, 2023 7:01am EDT

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

Jul 10, 2023 8:00am EDT

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

Jul 05, 2023 4:15pm EDT

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jun 29, 2023 8:00pm EDT

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Jun 06, 2023 7:35am EDT

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy Policy
Menu
  • Privacy Policy

© 2023 Intensity Therapeutics. All rights reserved.

Linkedin Twitter